Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

This study is ongoing, but not recruiting participants.

First Received: January 31, 2008 Last Updated: October 22, 2009 History of Changes

Sponsor:	Novartis
Collaborator:	Novartis Vaccines
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00616421

Purpose

This study will evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY conjugate vaccine

Condition	Intervention	Phase
Meningococcal Infections	Biological: MenACWY	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Single Blind (Subject), Single Group Assignment
Official Title:	A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age

Further study details as provided by Novartis:

Primary Outcome Measures:

To evaluate safety and immune response across groups at pre-defined time points [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

To further evaluate safety and immunogencity across groups at pre-defined time points [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]

Enrollment:	2820
Study Start Date:	February 2008
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
2: Experimental Children 2-5 years of age, 1 dose of MenACWY	Biological: MenACWY 1 dose of MenACWY
3: Active Comparator Children 2-5 years of age, 1 dose of MenACWY	Biological: MenACWY 1 dose of MenACWY
4: Experimental Children 6-10 years of age, 1 dose of MenACWY	Biological: MenACWY 1 dose of MenACWY
5: Active Comparator Children 6-10 years of age, 1 dose of MenACWY	Biological: MenACWY 1 dose of MenACWY
1: Experimental Children 2-5 years of age, Men ACWY Day 1 and Men ACWY Day 61	Biological: MenACWY 2 doses of MenACWY

Eligibility

Ages Eligible for Study:	2 Years to 10 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent
who are available for all visits and telephone calls scheduled for the study
who are up-to-date with age-appropriate routine childhood vaccinations

Exclusion Criteria:

whose parent or legal guardian is unwilling or unable to give written informed consent
who had a previous or suspected disease caused by N. meningitidis;
who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
who have received any investigational agents or vaccines within 90 days prior to enrollment
who have any serious acute, chronic or progressive disease
who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome
who have a history of anaphylaxis, serious vaccine reactions
who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from
who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
who have Down's syndrome or other known cytogenic disorders

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00616421

Show 61 Study Locations

Sponsors and Collaborators

Novartis

Novartis Vaccines

Investigators

Study Chair:

Novartis Vaccines

More Information

No publications provided

Responsible Party:	Novartis Vaccines ( Novartis )
Study ID Numbers:	V59P20, 11278
Study First Received:	January 31, 2008
Last Updated:	October 22, 2009
ClinicalTrials.gov Identifier:	NCT00616421 History of Changes
Health Authority:	United States: Food and Drug Administration; Canada: Health Canada

Keywords provided by Novartis:

vaccine
children
healthy

meningitis
meningococcal
Prevention of Meningococcal disease serogroups ACWY

Additional relevant MeSH terms:

Bacterial Infections
Infection
Meningococcal Infections
Gram-Negative Bacterial Infections
Neisseriaceae Infections

ClinicalTrials.gov processed this record on February 08, 2010